Nanolynx Biologics AG Verified listing Verified listing

  • Swiss Biotech Association
    Not a member

Nanolynx is developing conditionally active nanobody-drug conjugates that overcome the tissue penetration and toxicity limits of conventional ADCs, enabling safer and more efficacious therapies for hard-to-treat cancers.

Location
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2025
  • Number of employees in Switzerland
    1-9
Key business

You may also be interested in